Irlab Parkinson's Pact With Ipsen Up In The Air
Setback For Mesdopetam In Mid-Stage Study
The Swedish firm’s Parkinson's disease drug has failed to hit its primary endpoint in a Phase IIb study but Irlab believes that positive results on secondary goals merit further development of mesdopetam.
